Fig. 1: Risk of basal cell carcinoma, cutaneous squamous cell carcinoma, and cutaneous malignant melanoma according to cumulative methotrexate dose for all patients.
From: Use of methotrexate and risk of skin cancer: a nationwide case–control study
BCC basal cell carcinoma, CI confidence interval, CMM cutaneous malignant melanoma, cSCC cutaneous squamous cell carcinoma, MTX methotrexate, OR odds ratio.
